These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25919404)

  • 1. The Effect of Halogen-to-Hydrogen Bond Substitution on Human Aldose Reductase Inhibition.
    Fanfrlík J; Ruiz FX; Kadlčíková A; Řezáč J; Cousido-Siah A; Mitschler A; Haldar S; Lepšík M; Kolář MH; Majer P; Podjarny AD; Hobza P
    ACS Chem Biol; 2015 Jul; 10(7):1637-42. PubMed ID: 25919404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of aldose reductase inhibition by halogen bond tuning.
    Fanfrlík J; Kolář M; Kamlar M; Hurný D; Ruiz FX; Cousido-Siah A; Mitschler A; Rezáč J; Munusamy E; Lepšík M; Matějíček P; Veselý J; Podjarny A; Hobza P
    ACS Chem Biol; 2013 Nov; 8(11):2484-92. PubMed ID: 23988122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
    El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
    Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution.
    Steuber H; Heine A; Klebe G
    J Mol Biol; 2007 May; 368(3):618-38. PubMed ID: 17368668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor.
    Carbone V; Giglio M; Chung R; Huyton T; Adams J; Maccari R; Ottana R; Hara A; El-Kabbani O
    Eur J Med Chem; 2010 Mar; 45(3):1140-5. PubMed ID: 20036445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase.
    Wang Z; Ling B; Zhang R; Suo Y; Liu Y; Yu Z; Liu C
    J Mol Graph Model; 2009 Sep; 28(2):162-9. PubMed ID: 19616461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of aldose reductase inhibition and docking studies of some secondary metabolites, isolated from Origanum vulgare L. ssp. hirtum.
    Koukoulitsa C; Zika C; Geromichalos GD; Demopoulos VJ; Skaltsa H
    Bioorg Med Chem; 2006 Mar; 14(5):1653-9. PubMed ID: 16249088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the inhibitor-binding site of porcine aldehyde reductase: crystal structure of the holoenzyme-inhibitor ternary complex.
    el-Kabbani O; Carper DA; McGowan MH; Devedjiev Y; Rees-Milton KJ; Flynn TG
    Proteins; 1997 Oct; 29(2):186-92. PubMed ID: 9329083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP
    J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
    El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
    Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
    Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
    Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.
    Steuber H; Heine A; Podjarny A; Klebe G
    J Mol Biol; 2008 Jun; 379(5):991-1016. PubMed ID: 18495158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
    El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
    Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
    Sotriffer CA; Krämer O; Klebe G
    Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48.
    Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A
    Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
    El-Kabbani O; Old SE; Ginell SL; Carper DA
    Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, activity, and molecular modeling of new 2, 4-dioxo-5-(naphthylmethylene)-3-thiazolidineacetic acids and 2-thioxo analogues as potent aldose reductase inhibitors.
    Fresneau P; Cussac M; Morand JM; Szymonski B; Tranqui D; Leclerc G
    J Med Chem; 1998 Nov; 41(24):4706-15. PubMed ID: 9822541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and activity of a new series of (Z)-3-phenyl-2-benzoylpropenoic acid derivatives as aldose reductase inhibitors.
    Wang SJ; Yan JF; Hao D; Niu XW; Cheng MS
    Molecules; 2007 Apr; 12(4):885-95. PubMed ID: 17851441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A.
    Howard EI; Sanishvili R; Cachau RE; Mitschler A; Chevrier B; Barth P; Lamour V; Van Zandt M; Sibley E; Bon C; Moras D; Schneider TR; Joachimiak A; Podjarny A
    Proteins; 2004 Jun; 55(4):792-804. PubMed ID: 15146478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors.
    Jung HA; Moon HE; Oh SH; Kim BW; Sohn HS; Choi JS
    Chem Biol Interact; 2012 May; 197(2-3):110-8. PubMed ID: 22543015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.